Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RET Proto-Oncogene Mutation”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Not applicableUnknownNCT06081270
What this trial is testing

Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer

Who this might be right for
Lung Cancer
University of Milano Bicocca 20
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Testing effectiveness (Phase 2)Study completedNCT01813734
What this trial is testing

Ponatinib in Advanced NSCLC w/ RET Translocations

Who this might be right for
Non Small Cell Lung Cancer
Massachusetts General Hospital 9
Large-scale testing (Phase 3)Ended earlyNCT04222972
What this trial is testing

Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell Lung+14 more
Hoffmann-La Roche 223
Testing effectiveness (Phase 2)Ended earlyNCT04161391
What this trial is testing

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more
Turning Point Therapeutics, Inc. 41
Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Early research (Phase 1)Study completedNCT03784378
What this trial is testing

Continued Access to RXDX-105

Who this might be right for
Non Small Cell Lung CancerOvarian CancerRET Gene Mutation+1 more
Memorial Sloan Kettering Cancer Center 3
Not applicableNot Yet RecruitingNCT07042984
What this trial is testing

RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer

Who this might be right for
Papillary Thyroid CarcinomaThyroid NeoplasmsRET Proto-Oncogene Mutation+1 more
Fujian Medical University 800
Testing effectiveness (Phase 2)Looking for participantsNCT06109558
What this trial is testing

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Who this might be right for
Non Small Cell Lung CancerRET Gene MutationMET Amplification+1 more
Hunan Province Tumor Hospital 120